Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by PinnacleXon Dec 02, 2022 12:20am
136 Views
Post# 35145328

RE:RE:RE:RE:RE:RE:RE:Woe are us.

RE:RE:RE:RE:RE:RE:RE:Woe are us.
PWIB123 wrote: Oh, I see.  It's ok for you to twist "facts."  Got it.  A pop is not a pop unless the stock only goes up from there?  That's a brilliant definition to fit your negative narrative.  Can you show me that definition on Investopedia or anywhere, it's new to me?  It's obvious you're miserable.  I've read your posts for the last couple years.  Whatever has gone on in your life to make you think it's ok to try to project your own misery onto others, I am sorry.  Choose joy!  It's better over here.  You did, however, make me smile from this, so thank you for that.  Hey, you're already lightening things up around here.  Look at that!

PinnacleX wrote:
PWIB123 wrote: I saw the pop.  The stock jumped right off that 52 week low.  This is not the first time PinnacleX has ignored facts while accusing someone else of making up their own story.  You can never trust a man or woman like that.  

SPCEO1 wrote: Always glad to see you posting as it is highly correlated with the stock hitting a short term low. Feel free to look at a stock chart of THTX so you can see the pop it had after the Cantor report. My clients can fire me at any time, so that is accountability. Fortunately, we are having a really good year, probably the best of my entire career, so despite THTX's continuing travails, our clients are in a good spot. Hope you have a wonderful Christmas season! 

PinnacleX wrote:
SPCEO1 wrote: The Cantor report was, at best, OK and got us a nice, semi-temporary pop higher. The Jones report was really well done but I have no familiarity with Jones and their capabilities to influence a share price. Clearly, the report had almost no influence on the share price yesterday. Maybe it takes a longer period of time for the report to make its way through Jones distribution network before it creates demand for the stock. With an institutional broker like Cantor, the effect is typically immediate as their own trading desk get active right away trading the stock. With a retail brokerage firm, their trading desk is likely less important and reaction to t he recommnedation of their analyst plays out over time as individual investors are sold on THTX by their advisors? I really don't know so I am just guessing.

But the Jones report was a good one and put some meat on the case for TH-1902. In the end, however, positive data from the phase 1b is what the stock needs to have a powerful and sustainable move higher. Having more and better analyst coverage when such news is hopefully released will help propel the move higher. But without positive news on TH-1902 or maybe a surprise resurrecction of NASH, or both, there is only so much agood analyst report can do, particularly in a bear market for biotech stocks.

longterm56 wrote: Markets up 2-4%, many stocks up 5-8%, long awaited "impressive" analyst report with a BUY and x3 price target ... THTX declines. 

Merry Christmas?

    -LT

 

 


There was no pop, this is normal downward trend of a stock, its like you have no clue, you just m5 or so Pop Up over the last 3 years then come back. ake things up on the spot.  You've done this for years, you've made every possible excuse for this stock.  You say you run a fund, you have destroyed peoples lives by being obsessed with this horrendous stock and managament. I just wanna ask you if you have any accountablity whatsoever?

 

 

LOL who is this guy?  Ok look at the other 15 or so ""popups" over the last 3 years on its way down.  That means NOTHING.



You've been reading my posts for years, that right there says how miserable YOU really are.  Cant get enough.  LOL 
<< Previous
Bullboard Posts
Next >>